Possibly, and the evidence leans that way. A large records study followed people with a past episode of acute pancreatitis [1]. It came back in 13.8% of GLP-1 users. Among non-users it was 40.9%. That comparison is for people without other risk factors. It is observational, not a trial.
The label adds the rule. Watch for symptoms after starting. Stop if pancreatitis is suspected [3]. So a past episode is a question for a clinician, not a checkout. The drug-class picture is in the side-effect guide, where pancreatitis came back null.
The recurrence study
The study used the TriNetX records network. It covered 258,238 people with type 2 diabetes or obesity and a history of acute pancreatitis. Recurrence was tracked over five years.
Without other risk factors, recurrence was 13.8% on a GLP-1 and 40.9% without one. Semaglutide users recurred less than exenatide users: 10.1% against 27%. Against dulaglutide the gap was small, 13.6% against 15.4%, and not significant.
Tirzepatide showed the lowest figure, 6.2%, against 11.7% on semaglutide. The authors call for further studies. Records show who was prescribed what, not why.
What the trials show
A 2017 meta-analysis pooled 113 randomized trials in type 2 diabetes [2]. Pancreatitis was no more common on a GLP-1 than on comparators. The odds ratio was 0.93, with a 95% CI of 0.65 to 1.34.
Pancreatic cancer was also not raised: 0.94 (0.52 to 1.70). Gallstones were. The odds ratio for cholelithiasis was 1.30 (1.01 to 1.68). The gallstone side of that is in the gallbladder guide.
Most of those trials saw few events. Of the 113, 72 reported no pancreatitis in any group. Thirteen did not report it at all.
What the label says
Acute pancreatitis has been observed on GLP-1 drugs, including fatal cases. In the Wegovy weight trials, it was confirmed in 4 treated patients. That was 0.2 cases per 100 patient-years. On placebo it was 1 patient, under 0.1.
The label’s symptom is persistent or severe abdominal pain. It sometimes radiates to the back. Vomiting may or may not come with it. If pancreatitis is suspected, the drug is stopped. The same warning appears in the alcohol guide.
Chronic pancreatitis: one study, read carefully
A second records study matched 1,422 people with chronic pancreatitis on a GLP-1 to 1,422 without [4]. None had diabetes. Recurrent acute pancreatitis was recorded in 2.4% against 10.8%.
The study also reports far lower mortality on a GLP-1. A selected, healthier group explains that more easily than the drug does. The same paper appears in the longevity guide for that reason. The authors call their findings hypothesis-generating. They say the findings should not guide prescribing.
One result went the other way. Vitamin D deficiency had a higher hazard, 1.556. Its risk comparison was not significant. Eating less is one route to it, covered in the protein guide.
What this means for a buyer
A past episode of pancreatitis belongs on any intake form. Answer it plainly. An online prescriber can only weigh what the form records.
The records studies point one way, and the trials show no rise. Neither is a clearance for an individual. That call is the prescriber’s, with the history in front of them.